Notice is given under section 14(1) of the Agricultural Compounds and Veterinary Medicines Act 1997 (“Act”), of the following application to register a trade name product under section 9(1) of the Act:

Trade Name: Zenrelia

Registration Number: A012153

Active Ingredient and Concentration:

Each tablet contains 4.8mg, 6.4mg, 8.5mg or 15mg of ILUNOCITINIB

Formulation Type: Tablet

Application Method / Administration Route: Oral

Use Claim:

For the treatment of pruritus associated with allergic dermatitis and treatment of the clinical manifestations of atopic dermatitis in dogs.

Any person may make a written submission to the Director-General concerning this application.

Under sections 16 and 17 of the Act, a written submission:

1. must state in full the reasons for making the submission;
2. may state any decision sought on that application; and
3. must be received by the Director-General no later than 30 working days after the date of this notice.

Each submission must state the trade name product(s) to which it relates. Under section 18 of the Act, a copy of every submission will be forwarded to the applicant.

The following address is:

1. where submissions on this application are to be sent;
2. where requests for copies of the public information relating to the application can be sent;
3. where public information relating to the application can be viewed; and
4. the Director-General’s address for service:

ACVM Team, Ministry for Primary Industries, Charles Fergusson Building, 38–42 Bowen Street, Pipitea, Wellington 6011. Postal Address: PO Box 2526, Wellington 6140. Email: acvm.consultation@mpi.govt.nz.

MPI encourages submission by email.

The applicant’s address for service is:

Elanco Australasia Pty Ltd, 27/88 Shortland Street, Auckland 1010, New Zealand. Postal Address: Elanco Australasia Pty Ltd, 7 Eden Park Drive, Macquarie Park, NSW 2113, Australia.

Dated at Wellington this 15th day of April 2025.

JAMES MCBURNEY, Team Leader Country Listings, Approvals, Ministry for Primary Industries (acting under delegated authority).